Mohamud R Daya, Brian G Leroux, Paul Dorian, Thomas D Rea, Craig D Newgard, Laurie J Morrison, Joshua R Lupton, James J Menegazzi, Joseph P Ornato, George Sopko, Jim Christenson, Ahamed Idris, Purav Mody, Gary M Vilke, Caroline Herdeman, David Barbic, Peter J Kudenchuk
BACKGROUND: Antiarrhythmic drugs have not proven to significantly improve overall survival after out-of-hospital cardiac arrest from shock-refractory ventricular fibrillation/pulseless ventricular tachycardia. How this might be influenced by the route of drug administration is not known. METHODS: In this prespecified analysis of a randomized, placebo-controlled clinical trial, we compared the differences in survival to hospital discharge in adults with shock-refractory ventricular fibrillation/pulseless ventricular tachycardia out-of-hospital cardiac arrest who were randomly assigned by emergency medical services personnel to an antiarrhythmic drug versus placebo in the ALPS trial (Resuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study), when stratified by the intravenous versus intraosseous route of administration...
January 21, 2020: Circulation